Thank patent laws, not their critics, for generic GLP-1s
GUEST COLUMN, David Kappos, former director of U.S. Patent Office
In late June, generic drug maker Teva Pharmaceuticals launched a generic version of Victoza, a blockbuster diabetes drug, in the United States.
Victoza is one of the first GLP-1 drugs — the class of wildly popular diabetes and obesity treatments that includes Ozempic and Wegovy — to go off-patent.
Within just a couple of years, GLP-1 drugs have rewritten the rules of diabetes and obesity treatment, offering patients the kind of sustained weight loss and glycemic control that was once the stuff of infomercial fantasy.